Lilly's new drug approved in China and earnings surpass expectations, causing short-term stock price fluctuations

China Business Network, February 11, 2026 — Eli Lilly announced that its GLP-1/GIP drug, Tirzepatide (brand name: Mufenda), has been approved by the China National Medical Products Administration (NMPA) for the treatment of adult type 2 diabetes as a monotherapy. This approval is based on the Chinese early-stage patient-focused SURPASS-CN-MONO study and is expected to further expand its market potential in China. On the same day, Eli Lilly’s IL-23 monoclonal antibody, Migezhu (intravenous and subcutaneous formulations), was approved for marketing in China for the treatment of Crohn’s disease and ulcerative colitis, strengthening its presence in the immunology field.

Financial Report Analysis

On February 4, 2026, Eli Lilly released its Q4 and full-year 2025 financial results. Revenue for the fourth quarter reached $19.29 billion, a 43% increase year-over-year, surpassing market expectations; adjusted earnings per share were $7.54, up 42% year-over-year. The Tirzepatide series contributed $36.5 billion in revenue for the full year, making it the highest-selling drug globally. The company provided an optimistic outlook for 2026, expecting revenue between $80 billion and $83 billion, a roughly 25% increase.

Recent Stock Performance

Driven by better-than-expected earnings and product developments, Eli Lilly’s stock has experienced significant fluctuations recently. On February 4, 2026, the stock surged 10.33% in a single day to $1,107.12. The latest data shows that the closing price on February 11, 2026, was $1,015.21, down 0.96% for the day, with a trading volume of $2.649 billion. Over the past five trading days, the stock has declined a total of 8.30%, reflecting short-term market adjustments following positive news.

Institutional Opinions

CICC (601995) released a report on February 10, 2026, stating that Tirzepatide topped the “Drug King” list in 2025. Eli Lilly’s pipeline remains robust, with the oral GLP-1 drug Orforglipron expected to be approved in the second quarter of 2026, potentially becoming a new growth driver. The report maintains a neutral rating with a target price of $1,107. Institutional data shows that as of February 2026, 78% of institutional views are to buy or hold, reflecting market confidence in the long-term prospects of the GLP-1 sector.

The above content is compiled from publicly available information and does not constitute investment advice.